All In Biotech

NDA 202408 · Fera Pharms LLC

Avaclyr

Acyclovir · Ophthalmic · Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 29, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

396

92 Phase 3, 31 recruiting

FAERS reports

105,993

75,930 serious, 13,283 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 5, 2026.

AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus. AVACLYR (acyclovir ophthalmic ointment) 3%, a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated in the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.

Mechanism: Acyclovir is an antiviral drug [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AVACLYR · ACYCLOVIR 3% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · OINTMENT, OPHTHALMIC · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Acyclovir" as an intervention, any sponsor and status, largest first.

All 396 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue7,672
  • diarrhoea6,912
  • off label use5,962
  • pneumonia5,279
  • nausea5,176
  • death4,624
  • pyrexia4,396
  • drug ineffective4,312
  • rash3,986
  • dyspnoea3,292
  • asthenia3,097
  • headache3,013

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004607
2005768
2006745
2007796
20081,042
20091,086
20101,090
20111,920
20122,059
20131,477
20142,094
20155,011
20165,197
20176,430
20187,474
20198,431
20209,299
202110,945
202210,127
20238,392
20247,904
20258,078
20265,021

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 938 on PubMed

Sponsor: Fera Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.